Recursion (RXRX) announced the top-line results from the SYCAMORE trial, a Phase 2, 12-month, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and exploratory efficacy of REC-994 in patients with symptomatic Cerebral Cavernous Malformation. The trial achieved its primary endpoint, demonstrating that REC-994 had a comparable safety and tolerability profile to the placebo, with similar frequencies and severities of adverse events observed across the placebo, 200mg, and 400mg dosage arms over the 12-month treatment period.Recursion plans to present the trial data at an upcoming medical conference and aims to submit the findings for publication in a peer-reviewed scientific journal.The material has been provided by InstaForex Company – www.instaforex.com
- J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer - September 14, 2024
- DIRECTV Reaches Agreement To Restore Disney Networks And Streaming Services - September 14, 2024
- Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint - September 14, 2024
